{'fraction_non_alphanumeric': 0.022556390977443608, 'fraction_numerical': 0.0, 'mean_word_length': 5.771186440677966, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Management of bone metastasis originating from lung cancer].

The preceding molecular target therapies have prolonged the life expectancy of many lung cancer patients, and some lung cancer patients have become long-term survivors. On the other hand, the proportion of patients who suffer from complications with bone metastasis and skeletal-related events(SRE)is increasing. Through management of bone metastasis, the preservation of quality of life and functional independence can be better maintained. Zoledronic acid and denosumab are usable in clinical practice; However, there are many problems in regard to treatments for bone metastasis. Lung cancer patients should be treated with bone metastasis with the coordinating cooperation between orthopedists, radiotherapists and dental surgeons.